Ratio to receive upfront, and potential milestones and tiered royalty paymentsBOSTON, Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS). The collaboration leverages Ratio's radioligand therapy discovery and develop ...

A downtrend has been apparent in Novartis (NVS) lately with too much selling pressure. The stock has declined 10.9% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for s ...

The price trend for Novartis (NVS) has been bearish lately and the stock has lost 5.1% over the past two weeks. However, the formation of a hammer chart pattern in its last trading session indicates that the stock could witness a trend reversal soon, as bulls might have gained significant control over the price to help it find support.While the formation of a hammer pattern is a technical indication of nearing a bottom with potential exhaustion of selling pressure, rising optimism among Wall Street analysts ...

Novartis (NVS) has been beaten down lately with too much selling pressure. While the stock has lost 9.7% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. How to Determine if a Stock is Oversold We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional valuation metrics to find stocks that they believe are being undervalued by th ...

On Tuesday, Novartis AG NVS reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. Guidance: Novartis also raised its 2024 full-year guidance again this year. In a statement, Novartis said it expects full-year core operating income to grow by a "high teens" percentage, compared with previous guidance of a "mid-to-high teens" percentage. Novartis forecasts full-year sales growth in the low double digits, having previously guided for high-s ...

I'm an investment analyst with several years of clinical experience and a Master of Business Administration, now expanding my focus beyond biotech and healthcare into a range of sectors. Since 2017, I've had the privilege of sharing my insights on Seeking Alpha. My work emphasizes financial modeling techniques, such as Discounted Cash Flow (DCF) analysis, to uncover hidden assumptions within stock valuations across multiple industries. By deconstructing metrics like revenue growth rates and cash flow margin ...

Ad hoc announcement pursuant to Art. 53 LR Scemblix, a new first-line option for adults with CML, is first to show superior efficacy and favorable safety and tolerability profile in a Phase III trial vs. all standard of care (SoC) therapies1-3 Patients on Scemblix also had fewer dose reductions and half the rate of adverse reactions leading to treatment discontinuation1-3 Nearly 50% of CML patients do not meet efficacy milestones (MMR) with current SoC and almost 25% discontinue or switch therapies within o ...

Financial Data and Key Metrics Changes - In Q3 2024, Novartis reported a 10% increase in net sales and a 20% increase in core operating income in constant currency, with a core margin of 40.1%, reflecting a 340 basis point improvement year-over-year [8][34] - For the first nine months of 2024, net sales grew 11%, core operating income also increased by 20%, and core EPS was $5.83, up 21% [35][36] - Free cash flow reached $6 billion in Q3, the highest ever achieved in a single quarter, and $12.6 billion for the first nine months, a 15% increase [34][35] Business Line Data and Key Metrics Changes - Entresto's sales increased by 26% in Q3, marking its 10th consecutive year of growth, with strong performance in hypertension in China and Japan [11] - Cosentyx grew by 28%, driven by new launches, with a 38% increase in the U.S. and 16% outside the U.S. [12] - Kesimpta saw a 28% growth, with a 56% increase in constant currencies when excluding a one-time adjustment [14] - Kisqali achieved 43% growth, with a 50% increase in the U.S. and a 36% increase outside the U.S. [16] - Pluvicto grew by 50% in Q3, with a focus on preparing for the PSMAfore launch in 2025 [19] - Scemblix grew by 72% in Q3, becoming the preferred option for third-line CML [24] - Fabhalta received accelerated approval in the U.S. for IgA nephropathy, with strong early performance [28] Market Data and Key Metrics Changes - Novartis expects continued strong performance across key growth drivers, with a 5% sales growth guidance extended to 2028 [10] - The market for Cosentyx in HS is projected to expand significantly, potentially reaching over $5 billion [13] - The PSMAfore launch is expected to triple the patient population eligible for Pluvicto [20] Company Strategy and Development Direction - Novartis raised its full-year guidance for the third time, indicating strong underlying momentum across growth drivers and new launches [36][42] - The company is focused on innovation, with multiple Phase III readouts and submissions planned for key products [42] - Novartis is committed to a shareholder-friendly capital allocation strategy, including ongoing share buybacks and investments in R&D [38] Management's Comments on Operating Environment and Future Outlook - Management noted that the coverage gap reform in 2025 is expected to have a neutral impact on the business, with adjustments already factored into long-term guidance [47] - The company remains confident in its ability to grow top and bottom lines in 2025, despite anticipated headwinds from generic entries [53] - Management emphasized the importance of maintaining strong market positions for key products, particularly in the face of increasing competition [58] Other Important Information - Novartis is actively pursuing M&A opportunities to strengthen its pipeline and technology platforms, particularly in RLT and immunology [38][81] - The company is also focused on legislative efforts to amend the IRA, which could impact pricing and market access for its products [112][113] Q&A Session Summary Question: Impact of coverage gap reform on Cosentyx and Entresto - Management indicated that the coverage gap reform will have both positive and negative impacts, but overall is expected to be neutral and already factored into guidance [47] Question: Timing of promotional efforts for Pluvicto - Management stated that promotional efforts would take about six months to show impact, with significant growth expected post-PSMAfore launch [50] Question: Tailwinds and headwinds for 2025 - Management highlighted new indications and launches as tailwinds, while LoEs for certain products are anticipated as headwinds [54] Question: Competitive dynamics for Cosentyx in HS - Management expressed confidence in Cosentyx's market position due to strong clinical data and established relationships with dermatologists [58] Question: Growth expectations for Pluvicto - Management noted that growth in the ex-U.S. market is ongoing, but pricing dynamics are currently limiting revenue translation [62] Question: Kisqali patent expiry - Management confirmed that the estimated patent expiry for Kisqali in Europe is August 2032 [68] Question: Future M&A appetite - Management indicated a balanced approach to capital allocation, with ongoing share buybacks and M&A opportunities being pursued [81][92] Question: Impact of GLP-1s on Pelacarsen study - Management clarified that while GLP-1s have modest effects on Lp(a), the focus of the study is on patients with significantly elevated Lp(a) levels [77] Question: Update on IRA legislation - Management provided an update on ongoing legislative efforts to amend the IRA, highlighting bipartisan support for proposed changes [112][113]

Swiss pharma giant Novartis AG (NVS) reported better-than-expected results for the third quarter of 2024. Core earnings (excluding one-time charges) of $2.06 per share beat the Zacks Consensus Estimate of $1.94 and were up from $1.74 reported a year ago. The year-over-year growth was driven by an increase in sales. Revenues of $12.8 billion climbed 9% from the year-ago figure. On a constant currency basis, sales increased 10%, driven by the momentum in Entresto, Kesimpta, Kisqali, Cosentyx, Pluvicto and Leq ...